Congratulations on your new role as Chief Medical & Development Officer at Kyverna Therapeutics! After 16 years in leadership roles at Eli Lilly, what motivated your transition to Kyverna, and how has the shift been for you?
I’ve always been …
In oncology, breakthroughs in treatment are revolutionizing care for cancer patients worldwide. Antibody-Drug Conjugates (ADCs) represent a significant advancement, offering targeted therapies that precisely deliver potent drugs to cancer cells, minimizing damage to healthy tissue. To delve into the potential …
Q. As your company is part of the ecosystem that represented the fourth largest career path vertical for MIT Sloan’s Class of 2023[1], clearly there is interest in students entering this arena. How can MIT education be applied to …
How do you build solid analytics learning culture at Fortune 100 companies?
Xingchu: Analytics learning culture starts with analytics, and building a data analytics-first culture is critical. This approach means that for every business decision, we start from data and …
Q. Creating revenue growth and shareholder value are table stakes for aspiring CEOs. With over five-thousand participants in last year’s executive education programming offered at MIT Sloan[1], several of these leaders have ambitions to secure executive roles. As a …
Q. As the Senior Associate Dean of Yale’s School of Management once shared, “Having seen peer CEOs hang on his every word in private top leadership forums for many years, I have begged Fred Hassan to go public with this …
Q1. What are the major trends or developments that you believe will shape the digital surgery field over the next decade? How should companies prepare for and adapt to these trends to maximize their impact on the industry and improve …
Brain health is a notoriously difficult domain of medicine. What recent advancements excite you, and how can we foster continued innovation in this area?
Brain health is undoubtedly one of the most challenging areas of medicine, often called the “last …
Given that you have led big pharma (J&J) and smaller firms (Theravance and now Parabilis Medicines), what are the career prospects and trajectory for mid-career / newly graduating students wanting to enter this vertical? What would be your advice for prospective …
Q. With 24.1% of last year’s MIT Sloan class entering technology roles [1], which emerging technologies provide accelerators for the career trajectories of the MIT readership?
A. (Meyerson) While AI has and continues to be a hot topic across the …
